Modality
Gene Editing
MOA
BCL-2i
Target
KRASG12D
Pathway
Neuroinflam
NASH
Development Pipeline
Preclinical
~Oct 2022
→ ~Jan 2024
Phase 1
Apr 2024
→ Jul 2031
Phase 1Current
NCT08696760
1,157 pts·NASH
2024-04→2031-07·Recruiting
1,157 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-07-275.3y awayPh2 Data· NASH
Trial Timeline
Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3
P1/2
Recruit…
Catalysts
Ph2 Data
2031-07-27 · 5.3y away
NASH
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08696760 | Phase 1/2 | NASH | Recruiting | 1157 | Safety |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5501 | Pfizer | Phase 1 | BTK | |
| RHH-3592 | Roche | Phase 1/2 | GIP-R | |
| Rilulemzoparlimab | Novartis | Phase 2/3 | KRASG12D | |
| Geliderotide | Novartis | NDA/BLA | IL-17A | |
| BMY-2495 | Bristol-Myers Squibb | Phase 3 | KRASG12D | |
| SNY-2934 | Sanofi | Phase 3 | KRASG12D | |
| Talainavolisib | Novo Nordisk | Preclinical | KRASG12D | |
| Tezecilimab | Takeda | NDA/BLA | Tau | |
| Rimaosocimab | Amgen | Preclinical | FXIa | |
| GIL-2037 | Gilead Sciences | Approved | KRASG12D |